Markedly Enhanced Cytolysis by <i>E1B-19kD</i> -Deleted Oncolytic Adenovirus in Combination with Cisplatin

A‐Rum Yoon(Hanyang University), Chae‐Ok Yun(Hanyang University), Hoguen Kim(Yonsei University), Joohyuk Sohn(Yonsei University), Joo-Hang Kim(CHA University Bundang Medical Center), Byeong‐Woo Park(University Health System), Youngsook Lee(University of Wisconsin–Madison), Ji Young Yoo(The University of Texas MD Anderson Cancer Center)

Human Gene Therapy

April 1, 2006

10.1089/hum.2006.17.379

Cited by 49

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

|New England Journal of Medicine|2022|2.5k

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

|Journal of Clinical Oncology|2017|1.7k

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

|The Lancet|2020|1.1k

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

|New England Journal of Medicine|2019|1k

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

|The Lancet Oncology|2018|1k